Overview
Tirzepatide is classified as a dual agonist (glp-1/gip) peptide. Weight loss, body recomposition, glycemic control.
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Also known as: Mounjaro, Zepbound
Category
Dual Agonist (GLP-1/GIP)
Half-Life
120h
Route
SubQ
FDA Status
Approved
How Does Tirzepatide Work?
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
At the molecular level, Tirzepatide operates through pathways characteristic of the Dual Agonist (GLP-1/GIP) class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Tirzepatide Phase 3 SURMOUNT-1: up to 22.5% weight loss
Jastreboff et al. (NEJM): Phase 3 SURMOUNT-1 trial tirzepatide 15mg achieved 22.5% body weight reduction vs 2.4% placebo at 72 weeks in 2,539 adults with obesity.
Evidence: very strong[2]SURMOUNT-4: 176-week long-term weight maintenance
Aronne et al.: 176-week data showing sustained weight loss maintenance with continued tirzepatide treatment 15mg dose maintained -19.7% weight reduction.
Evidence: very strong[3]Tirzepatide meta-analysis: BMI, weight, and metabolic outcomes
Meta-analysis of multiple RCTs confirming tirzepatide significantly reduces BMI, waist circumference, body weight, and HbA1c across diverse patient populations.
Evidence: very strong[4]SURPASS program: tirzepatide in type 2 diabetes (Phase 3)
Frias et al. (NEJM): SURPASS-1 trial showing tirzepatide reduces HbA1c by up to 2.07% and body weight by 9.5 kg in type 2 diabetes. Superior to semaglutide in head-to-head trials.
Evidence: very strongSafety Profile
FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). GI side effects common but manageable. Well-studied long-term safety.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~32% of users | moderate |
| Diarrhea | ~23% of users | mild |
| Vomiting | ~20% of users | moderate |
| Constipation | ~18% of users | mild |
| Hypoglycemia | ~5% of users | moderate |
Sourcing Tirzepatide for Research
If you're looking to source Tirzepatide for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
Tirzepatide — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.